• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Eli Lilly & Company - Articles and news items

Alzheimer's disease definition

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease

Industry news / 23 August 2016 / AstraZeneca

AstraZeneca and Eli Lilly and Company have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in Phase III clinical trial.

metastatic breast cancer

Lilly and Boehringer Ingelheim take on metastatic breast cancer

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Lilly and Boehringer Ingelheim are to collaborate on a Phase Ib study of abemaciclib and BI 836845 in patients with HR+, HER2- metastatic breast cancer…

jardiance

Jardiance reduces risk of progressive kidney disease in type 2 diabetes

Industry news / 14 June 2016 / Victoria White, Digital Content Producer

Jardiance reduced the risk for new-onset or worsening kidney disease by 39% versus placebo in adults with type 2 diabetes with established CV disease…

jardiance

Jardiance data shows reduced risk of CV death in type 2 diabetes

Industry news / 13 June 2016 / Victoria White, Digital Content Producer

New data for Jardiance (empagliflozin) show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes…

trulicity

New data for Trulicity and Tradjenta in type 2 diabetes

Industry news / 13 June 2016 / Victoria White, Digital Content Producer

Lilly has announced new findings from separate studies of Trulicity and Tradjenta at the American Diabetes Association 76th Scientific Sessions…

baracitinib

New data for baricitinib in rheumatoid arthritis presented at EULAR

Industry news / 9 June 2016 / Victoria White, Digital Content Producer

Findings from the RA-BEYOND study demonstrate that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage…

nsclc

Data for Alimta and Cyramza plus keytruda in NSCLC presented at ASCO

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Data were presented from two early-phase trials evaluating Lilly’s Alimta and Cyramza in combination with Merck’s Keytruda in patients with NSCLC…

taltz

Lilly’s psoriasis drug Taltz to generate sales over $1 billion by 2022

Industry news / 11 May 2016 / Victoria White, Digital Content Producer

Taltz is set to generate sales in excess of $1 billion in the US and EU due to its high clinical efficacy and good safety profile, according to GlobalData…

olaratumab

FDA grants Priority Review for olaratumab BLA

Industry news / 4 May 2016 / Victoria White, Digital Content Producer

Lilly’s biologics license application is for olaratumab in combination with doxorubicin for the treatment of people with advanced soft tissue sarcoma…

biochaperone lispro

Positive topline results from a Phase Ib study of BioChaperone Lispro

Industry news / 28 April 2016 / Victoria White, Digital Content Producer

Adocia and Lilly have announced positive topline results from a Phase Ib trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro…

ixekizumab

EC grants marketing authorisation to Lilly’s ixekizumab

Industry news / 26 April 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation for Lilly’s ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults…

chronic heart failure

Jardiance to be investigated in chronic heart failure trials

Industry news / 19 April 2016 / Victoria White, Digital Content Producer

Boehringer Ingelheim and Lilly have announced plans to conduct two trials investigating Jardiance for the treatment of people with chronic heart failure…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +